Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Galcanezumab benefits patients with migraine and medication overuse

Publish date:: August 22, 2019

Key clinical point: Galcanezumab has clinical benefits for patients with migraine and medication overuse.

Major finding: Among patients with medication overuse who received galcanezumab, 85% of those with episodic migraine and 50% of those with chronic migraine had a reduction in medication overuse.

Study details: A post hoc analysis of 1,285 patients with migraine and medication overuse in three phase 3 studies of galcanezumab.

Disclosures: The investigators are employees of Eli Lilly, which developed galcanezumab and funded the studies.

Citation:

Aurora S et al. AHS 2019. Abstract IOR07.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Headache & Migraine

HIT-6 may help track meaningful change in chronic migraine,

Choroid plexuses may play a role in migraine,

Multiple traits more common in difficult-to-treat patients with migraine,

Marijuana for migraine? Some tentative evidence,

Low vitamin D levels in patients with migraine,